Celloram proudly highlights the remarkable advancements made by Genfit, a global leader in liver disease therapeutics, on CLM-022, an investigational first-in-class NLRP3 inflammasome inhibitor initially developed by Celloram and exclusively out-licensed to Genfit in 2023. During the American Association for the Study of Liver Diseases (AASLD) International Meeting, held in San Diego from November 15–19, 2024, Genfit presented compelling data showcasing the therapeutic potential of CLM-022 for Acute-on-Chronic Liver Failure (ACLF).
ACLF is a severe syndrome marked by hepatic and extrahepatic organ failure, often triggered by infections and carrying a short-term mortality rate of 23% to 74% within 28 days. The condition affects approximately 294,000 patients across the US, EU4, and UK, with the prevalence projected to rise to 300,000 by 2036 due to aging populations and lifestyle-related factors. Despite its gravity, ACLF currently lacks approved therapies beyond supportive care and limited liver transplant availability, leaving patients and clinicians with significant unmet needs.
Genfit’s presentation at AASLD focused on the critical role of the NLRP3 inflammasome in ACLF progression. The inflammasome drives inflammation by converting danger signals [CA1] into the release of IL-1β and IL-18, and triggering pyroptosis, a highly inflammatory form of cell necrosis.
Genfit showcased preclinical studies demonstrating the capacity of investigational drug CLM-022 to effectively suppress inflammasome complex formation, significantly reduce IL-1β secretion, and mitigate pyroptosis. In a preclinical animal model of acute liver failure, CLM-022 demonstrated substantial reductions in liver damage and inflammation, offering a strong foundation for its potential as a groundbreaking therapy in ACLF treatment.
“The data presented by Genfit highlights the transformative potential of CLM-022 as a potential novel therapeutic approach for ACLF,” said Dr. Seunghwan Lim, Vice President and Director of Scientific Programs at Celloram. “Celloram is proud to have partnered with Genfit in this endeavor, and their commitment to advancing this program has been exceptional.”
[CA1]Discretionary comment: consider alternative wording as it is not clear what ‘danger signals’ refers to.
